|
||||
|
||||
Patent Metrics: The Mismeasure of Innovation in the Biotech Patent Debate
David E. Adelman University of Texas School of Law Kathryn L. DeAnglis Piper Marbury Rudnick & Wolfe LLP Arizona Legal Studies Discussion Paper No. 06-10 Texas Law Review, Vol. 85, p. 1677, 2007 Abstract: The view that biotechnology patenting has reached unsustainable levels is well accepted among many legal scholars. This Article presents the first comprehensive empirical study of biotechnology patents. Our analysis reveals the striking rise and fall in patenting, the surprisingly diffuse pattern of patent ownership, and a consistent influx of new entrants conducting biotechnology research and development. This Article finds little evidence that the rise in biotechnology patenting is adversely affecting innovation. Counting patents, as it turns out, offers few insights on its own. One must also have a measure of the geographic scope of the scientific commons and the distribution of patents within it. These findings lead to a cautionary corollary for patent metrics generally - fundamental uncertainties associated with the statistics of innovative success cannot be overcome by sophisticated empirical methods. Ironically, the current enthusiasm for empirical work may have caused academics to reify abstract statistics over the obvious complexity of innovative processes.
Keywords: biotechnology, patents, statistics, metrics Accepted Paper SeriesDate posted: February 07, 2006 ; Last revised: July 02, 2007Suggested CitationContact Information
|
|
|||||||||||||||
© 2009 Social Science Electronic Publishing, Inc. All Rights Reserved. Terms of Use Privacy Policy
This page was served by apollo 4 in 0.141 seconds.